Principal Financial Group Inc. Purchases 1,059,394 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Principal Financial Group Inc. increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 785.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,194,221 shares of the biotechnology company's stock after acquiring an additional 1,059,394 shares during the period. Principal Financial Group Inc. owned approximately 0.51% of ADMA Biologics worth $23,872,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the second quarter valued at approximately $29,000. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics in the third quarter worth $30,000. Larson Financial Group LLC acquired a new stake in shares of ADMA Biologics in the third quarter valued at $31,000. National Bank of Canada FI acquired a new position in shares of ADMA Biologics during the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of ADMA Biologics during the third quarter worth approximately $62,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.70% of the company's stock.

ADMA Biologics Trading Up 2.8 %

Shares of ADMA Biologics stock traded up $0.48 during trading hours on Thursday, reaching $17.89. 1,623,457 shares of the company's stock were exchanged, compared to its average volume of 3,549,937. ADMA Biologics, Inc. has a 52-week low of $4.36 and a 52-week high of $23.64. The company has a fifty day moving average of $18.99 and a 200-day moving average of $16.49. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $4.23 billion, a price-to-earnings ratio of 63.89 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the company posted $0.01 EPS. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on ADMA. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.